Blockbuster Biologics 2013
- Category: FREE Reports
- Published on Friday, 02 January 2015 02:00
- Hits: 6632
This FREE Download contains a compilation of the 2013 sales of recombinant biologic products including antibodies and proteins. The report provides an overview of the blockbuster biologics with sales exceeding US$ 1 bln and 2013 sales for each class of biologics. .
Blockbuster Biologics 2013
Blockbuster Biologics Sales
The sales of the best selling antibodies and proteins in 2013 are listed up, each of them posting more than US$ 1 bln sales in 2013.
Therapeutic Proteins Sales
The report compiles 2013 sales of the major therapeutic proteins per class: erythropoietin, insulin and insulin analogs, coagulation factors, interferon alpha, interferon beta, granulocyte colony-stimulating factor (G-CSF), human growth hormone (hGH), enzyme replacement therapy and follicle stimulating hormone (FSH).
2013 sales of epoetin alfa and epoetin beta from Amgen, Johnson & Johnson (J&J), Roche, Chugai and Kyowa Hakko Kirin are presented for their products Aranesp, Procrit, Eprex, Epogen, ESPO, Neorecormon, Epogin, Mircera and Binocrit.
Insulin & Insulin Analogs
2013 sales of insulin and insulin analog products from Novo Nordisk, Eli Lilly and Sanofi are presented for their products Humalog (insulin lispro), Humulin, Lantus (insulin glargine), Levemir and Novolog (insulin analogue detemir and aspart) as well as for Actrapid, Novolin and others.
2013 sales of recombinant coagulation factor products factor VIIa, VIII and IX from Novo Nordisk, Bayer HealthCare Pharmaceuticals, CSL, Baxter and Pfizer are presented for their products Novoseven (eptacog alfa), Kogenate FS (octocog), Helixate FS, Advate, Recombinate, Refacto AF, Benefix (nonacog).
Interferon alpha and beta
2013 sales of recombinant interferon beta and alfa products are presented for Avonex, Rebif, Betaferon / Betaseron and Extavia from Biogen Idec, Merck Serono ,Bayer HealthCare Pharmaceuticals and Novartis as well as for Pegasys and Peg-Intron from Roche and Merck & Co.
Granulocyte Colony-Stimulating Factor (G-CSF)n
2013 sales of recombinant G-CSF products are presented for Neulasta (peg-filgrastim), Neupogen (filgrastim), GRAN (filgrastim), and Neutrogin (lenograstim) from Amgen, Kyowa Hakko Kirin and Chugai.
Human Growth Hormone (hGH)
2013 sales of recombinant human growth hormone (somatostatin) products are presented for Genotropin, Norditropin, Humatrope, Nutropin / Protropin and Saizen from Pfizer, Novo Nordisk, Eli Lilly, Genentech / Roche / Ipsen and Merck Serono.
Enzyme Replacement Therpay (ERT)
2013 sales of recombinant human enzyme products for treatment of metabolic diseases such as Gaucher’s disease, Fabry disease and Pompé disease are presented for Cerezyme (imiglucerase), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alfa), Aldurazyme (laronidase), Elaprase (idursulfase), Replagal (agalsidase alfa), VPRIV (velaglucerase) and Naglazyme (galsulfase) from Sanofi, Biomarin, Shire and Dainippon Sumitomo.
Follicle Stimulating Hormone (FSH)
2013 sales of recombinant follicle stimulating hormone (FSH) products for treatment of infertility are presented for Gonal-f (follitropin alfa) and Puregon / Follistim (follitropin beta) from Merck Serono and Merck & Co..
Other Therapeutic Proteins
2013 sales other therapeutic proteins including botulinum toxin products Botox and Dysport/Reloxin, Pulmozyme, InductOs, TNKase, Recotrhom, Erwinaze, Kalbitor, Hylenex, Kineret, Increlex, Kepivance, Neuart and Somavent.
Therapeutic Antibodies Sales
The report compiles 2013 sales of therapeutic antibodies per class: cancer antibodies, anti-TNF antibodies, other anti-inflammatory antibodies, ophthalmic and antiviral antibodies as well as other therapeutic antibodies.
2013 sales of recombinant monoclonal antibody products are presented for Rituxan / MabThera (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab), Erbitux (cetuximab) and Vectibix (panitumumab), Arzerra, Zevalin, XGEVA, Removab, Adcetris, Perjeta and Yervoy from Genentech / Roche, Bristol-Myers Squibb, Merck Serono, Eli Lilly, Fresenius Biotech, GlaxoSmithKline, Spectrum Pharmaceuticals, Amgen, and Seattle Genetics.
2013 sales of recombinant monoclonal antibodies and fusion proteins targeting tumor necrosis factor alpha (TNF) are presented for Enbrel (etanercept), Remicade (infliximab), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab) from Amgen, Pfizer, Takeda Pharmaceutical Co., Centocor (J&J), Merck, Tanabe Seiyaku, Abbott, Eisai and UCB.
Other Anti-Inflammatory Antibodies
2013 sales of recombinant monoclonal antibodies and fusion proteins such as Actemra/RoActemra, Orencia, Tysabri, Xolair, Soliris, Stelara, Ilaris, Arcalyst, Nulojix and Benlysta from Roche, Bristol-Myers Squibb, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Biogen Idec, Alexion Pharmaceuticals, GlaxoSmithKline.
2013 sales of the recombinant humanized antibody Synagis (palivizumab) targeting respiratory syncytial virus (RSV) for prevention of RSV infection in premature infants from MedImmune (AstraZeneca) are presented.
2013 sales of the VEGF targeting products Lucentis and Eylea for treatment of age-related macular degeneration from Genentech (Roche), Novartis, Regeneron Pharmaceuticals and Bayer HealthCare Pharmaceuticals are presented.
2013 sales of the recombinant therapeutic antibodies ReoPro, Prolia and Nplate.
Table of Content
- Top Selling Classes of Biological Products
- Top Blockbuster Biologics
- Cancer Antibodies
- Anti-TNF Biologics
- Insulin Products
- Erythropoiesis Stimulating Agents
- Rec. Coagulation Factors
- Interferon beta
- Other Anti-Inflammatory Antibodies
- Ophthalmic Antibodies
- Human Growth Hormone
- Interferon alfa
- Enzyme Replacement
- Follicle Stimulating Hormones
- Antiviral Antibody
- Other Antibodies
- Other Proteins